vVardis Valuation, Funding & Investors

vVardis is valued at $1B as of April 2026.

Last vVardis valuation

$1B

Undisclosed stage · Apr 2026

Last vVardis funding round

$300M

Undisclosed stage · Apr 2026

Cumulative funding vVardis raised

$387M

across 4 funding rounds

Key investors in vVardis

vVardis Overview

About vVardis

vVardis is a Switzerland-based oral care brand offering professional CURODONT dental repair products and consumer lines powered by CUROLOX and WX technologies. The range includes toothpaste, mouthwashes, and enamel repair kits distributed globally through dental clinics and pharmacies, targeting remineralization without fluoride.


Founded

2003

HQ

SwitzerlandBaar

Status

Privately held

Customer focus

B2C & B2B

Revenue model

Product sales

Valuation

$1B (Apr 2026)

vVardis Valuation

vVardis is currently valued at $1B, based on its undisclosed-stage round in April 2026.

The $300M round was led by Apollo Global Management.

vVardis valuation by funding round

vVardis valuation by funding round
DateStageValuation
Apr 2026Undisclosed stage$1B

vVardis Funding History

vVardis has raised a total of $387M across 4 funding rounds.

vVardis' first fundraising round was a $2M seed round in October 2022. The most recent completed round was a $300M undisclosed-stage round in April 2026.

vVardis funding rounds

vVardis funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Apr 2026Undisclosed stageApollo Global Management (lead)$300M$1BApollo-managed funds made a strategic minority investment in vVARDIS Holding AG on April 27, 2026, via issuance of convertible preferred stock. The investment valued the company at over $1 billion post-money, establishing it as a unicorn and one of Europe’s few privately owned billion-dollar-plus healthcare companies. Founders and co-CEOs Drs. Haley and Goly Abivardi retained a substantial majority shareholding. The investment supports vVARDIS’ next phase of global growth and commercial expansion, including rollout of the Curodont™ suite of products across key markets in the US and Europe. It strengthens commercial foundations and scales the environmentally sustainable, non-invasive peptide-based technology for drill-free cavity treatment, backed by peer-reviewed clinical studies. Apollo views vVARDIS as having built a differentiated business pioneering a new category in dental care. vVARDIS Holding AG is a high-growth Swiss dental medtech company based in Zug, specializing in non-invasive cavity treatment through its Curodont™ technology platform, the first peptide-containing formulations to regenerate early-stage tooth decay throughout the lesion depth. The company ranked first in growth rate in 2024 vs 2023 and YTD June 2025 among dental manufacturers with over $1M sales in both periods.
Jul 2025Undisclosed stageOrbiMed (lead)$50M-vVARDIS, a Swiss dental company based in Zug, develops Curodont, a drill-free, biomimetic treatment for early tooth decay that promotes enamel regeneration using saliva minerals as a non-invasive alternative to drilling and filling. On July 15, 2025, vVARDIS secured $50 million in new equity funding from OrbiMed, led by OrbiMed, bringing total financing from the investor to $85 million after an initial $35 million investment in February 2025. The funds will refinance existing facilities and accelerate global commercial expansion, including scaling sales teams and distribution for Curodont in the US and worldwide. Since January 2024, Curodont has treated over one million teeth in the US, achieving adoption in nearly 10% of US dental practices by mid-2025, signaling strong market traction amid shifts toward minimally invasive dentistry and AI-aided early decay detection. Partnerships include Henry Schein as exclusive US distributor for Curodont Repair Fluoride Plus (announced July 24, 2025), Pearl for AI detection integration (May 2025), and VideaHealth for enhanced diagnostics (June 2024). OrbiMed's Matthew Rizzo highlighted the product's momentum post-initial investment. Founders and co-CEOs Drs. Haleh and Golnar Abivardi emphasized the funding's role in elevating global standards for early decay treatment, targeting tooth decay as the WHO's top non-communicable disease. William Blair advised financially, with McGuireWoods and Rüd Winkler Partner providing legal support.
Feb 2025Undisclosed stageOrbiMed (lead)$35M-vVARDIS is a Swiss high-growth dental company that develops and manufactures non-invasive dental products under the Curodont brand. The company's flagship product, Curodont, is a drill-free treatment for early tooth decay that uses a biomimetic formulation to arrest and remineralize initial carious lesions without requiring a needle or drill. Curodont has been adopted by thousands of dental clinics in the United States and European Union and is incorporated into lectures at renowned universities as an emerging option for early caries management. vVARDIS secured $35 million in funding from OrbiMed in February 2025, followed by an additional $50 million in July 2025, bringing total capital secured from the healthcare investor to $85 million. The initial February investment was designed to accelerate Curodont rollout in the US by scaling clinical and sales teams, developing distribution infrastructure, and deepening engagement with dental professionals. The July funding round built on OrbiMed's positive experience with the company's momentum, citing the product's rapid progress and strong market response as reasons for deepening the investment. By mid-2025, Curodont had achieved significant clinical adoption. The company reported that the product was offered in nearly 10 percent of US dental offices and had treated over one million teeth within 18 months of launch. In July 2025, Henry Schein expanded its partnership with vVARDIS, becoming the exclusive distributor of Curodont Repair Fluoride Plus across all US dental segments. Additionally, the company collaborated with Pearl AI to integrate early detection capabilities with Curodont's drill-free treatment approach, and partnered with VideaHealth to combine improved diagnostic capabilities with early caries treatment solutions.
Oct 2022Seed-$2M--

Who has invested in vVardis?

2 investors have backed vVardis across its funding rounds, including OrbiMed and Apollo Global Management.

Lead investors include Apollo Global Management and OrbiMed.


vVardis Investors

Investors in vVardis by funding rounds participated
InvestorHQRoundsRoleFirst check

This data is available for Pro users. Sign up to see all 2 vVardis investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Acquisitions by vVardis

vVardis has acquired 1 company to date.

Last acquisition by vVardis was on December 9th 2020. vVardis acquired Credentis for undisclosed valuation.


Latest Acquisitions by vVardis

Credentis
Description
Credentis is a Windisch-based Swiss dental biotechnology firm founded in 2010 that commercializes bioactive products for enamel and dentin repair. Its portfolio includes Curodont Repair for non-invasive caries treatment, Curodont Protect for hypersensitivity relief, and Curodont D’Senz desensitizing agent, distributed in over 30 countries through partnerships with Henry Schein and Kerr. Clinically validated in peer-reviewed studies, Credentis products utilize self-assembling peptide technology to regenerate tooth structure without drilling.
HQ CountrySwitzerland
HQ City
Windisch
Deal Date9 Dec 2020
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all vVardis acquisitions and their M&A valuation multiples.

Start Free Trial

vVardis Competitors

vVardis competitors include listed companies like Cosmecca Korea and Chicmax Cosmetic, and private ones like Augustinus Bader, Haydon, KKW Beauty and Mamaearth.

Public and private companies comparable to vVardis
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
Augustinus BaderUnited KingdomLondonPrivate$100M-$1B10.0x
HaydonChinaShanghaiPrivate--$1B-
KKW BeautyUnited StatesLos Angeles, CAPrivate$100M-$1B10.0x
MamaearthIndiaGurgaonPrivate$100M-$1B10.0x
Cosmecca KoreaSouth KoreaSouth KoreaPublicly listed$467M$71M$1B2.1x
Chicmax CosmeticChinaChinaPublicly listed$1.4B$235M$1.1B0.8x

vVardis Public Comps

vVardis is still privately-owned, but its public comps include Cosmecca Korea, Chicmax Cosmetic, Procter & Gamble Health, Mega Lifesciences, T Hasegawa, Sarantis Group, ODDITY Tech, Menicon, Safilo Group and Synsam.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Cosmecca Korea$467M$71M2.5x2.1x16.5x12.9x
Chicmax Cosmetic$1.4B$235M0.8x0.8x4.5x7.3x
Procter & Gamble Health$144M$48M6.4x6.0x19.1x18.3x
Mega Lifesciences$425M$82M2.0x1.9x10.2x8.4x
T Hasegawa$472M$96M1.5x1.4x7.2x-
Sarantis Group$690M$104M1.3x1.3x8.7x8.3x
ODDITY Tech$810M$131M1.5x1.8x9.6x18.3x
Menicon$807M$131M1.4x1.4x8.8x8.3x

This data is available for Pro users. Sign up to see all vVardis competitors and their valuation data.

Start Free Trial

Common questions about vVardis

When was vVardis founded?vVardis was founded in 2003.
Where is vVardis headquartered?vVardis is headquartered in Baar, Switzerland.
Is vVardis publicly listed?No, vVardis is a private, VC-backed company.
What is vVardis' valuation?vVardis was last valued at $1B in its undisclosed-stage round in April 2026.
How much funding has vVardis raised?vVardis has raised $387M across 4 funding rounds.
What was vVardis' last funding round?vVardis' last funding round was a $300M undisclosed-stage round in April 2026, led by Apollo Global Management.
Who are vVardis' investors?vVardis' investors include OrbiMed and Apollo Global Management.
Which companies are comparable to vVardis?Companies comparable to vVardis include Augustinus Bader, Haydon, KKW Beauty, Mamaearth, Cosmecca Korea and Chicmax Cosmetic.
How many companies has vVardis acquired?vVardis has acquired 1 company, including Credentis.

See companies similar to vVardis

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial